PL365789A1 - Kompozycje oraz sposoby leczenia i diagnozowania nowotworów związanych z Her-2/neu - Google Patents
Kompozycje oraz sposoby leczenia i diagnozowania nowotworów związanych z Her-2/neuInfo
- Publication number
- PL365789A1 PL365789A1 PL01365789A PL36578901A PL365789A1 PL 365789 A1 PL365789 A1 PL 365789A1 PL 01365789 A PL01365789 A PL 01365789A PL 36578901 A PL36578901 A PL 36578901A PL 365789 A1 PL365789 A1 PL 365789A1
- Authority
- PL
- Poland
- Prior art keywords
- neu
- diagnosis
- compositions
- treatment
- methods
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22515200P | 2000-08-14 | 2000-08-14 | |
| US23642800P | 2000-09-28 | 2000-09-28 | |
| US27052001P | 2001-02-21 | 2001-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL365789A1 true PL365789A1 (pl) | 2005-01-10 |
Family
ID=27397445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01365789A PL365789A1 (pl) | 2000-08-14 | 2001-08-14 | Kompozycje oraz sposoby leczenia i diagnozowania nowotworów związanych z Her-2/neu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20020193329A1 (pl) |
| EP (1) | EP1366153A2 (pl) |
| JP (1) | JP2004522412A (pl) |
| KR (1) | KR20030048009A (pl) |
| CN (1) | CN1537164A (pl) |
| AU (1) | AU2001295008A1 (pl) |
| BR (1) | BR0113235A (pl) |
| CA (1) | CA2419533A1 (pl) |
| HU (1) | HUP0600780A2 (pl) |
| IL (1) | IL154415A0 (pl) |
| MX (1) | MXPA03001389A (pl) |
| NO (1) | NO20030714L (pl) |
| PL (1) | PL365789A1 (pl) |
| WO (1) | WO2002014503A2 (pl) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4658423B2 (ja) | 1999-08-03 | 2011-03-23 | ザ オハイオ ステイト ユニバーシティ | Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
| TWI259206B (en) * | 2002-09-24 | 2006-08-01 | Univ Nat Cheng Kung | A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof |
| EP1583833A1 (en) * | 2003-01-03 | 2005-10-12 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Rhesus her2/neu, nucleotides encoding same, and uses thereof |
| CN100558894C (zh) * | 2003-07-21 | 2009-11-11 | P.安杰莱蒂分子生物学研究所 | 编码人表皮生长因子2/neu抗原的合成基因及其用途 |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
| US7691396B2 (en) * | 2005-06-15 | 2010-04-06 | The Ohio State University Research Foundation | Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes |
| KR101010063B1 (ko) * | 2008-07-25 | 2011-01-21 | 삼표이앤씨 주식회사 | 레일고정구조 |
| US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| JP2013504585A (ja) | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SG185428A1 (en) | 2010-06-08 | 2012-12-28 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| PT2750713E (pt) | 2011-10-14 | 2016-01-20 | Genentech Inc | Pirrolobenzodiazepinas e conjugados das mesmas |
| CN102357246B (zh) * | 2011-11-02 | 2013-04-03 | 江苏省中医药研究院 | 一种egfr与her2联合多肽表位疫苗 |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| ES2649990T3 (es) | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
| US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| NZ707486A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| ES2738310T3 (es) | 2012-10-12 | 2020-01-21 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| EP2906296B1 (en) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| HK1216176A1 (zh) | 2012-12-21 | 2016-10-21 | Medlmmune Limited | 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| BR112015014669B1 (pt) | 2012-12-21 | 2023-09-26 | Medimmune Limited | Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| CN105142674B (zh) | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
| AU2014244245C1 (en) | 2013-03-13 | 2018-04-19 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| JP6993084B2 (ja) | 2013-08-12 | 2022-02-03 | ジェネンテック， インコーポレイテッド | １－（クロロメチル）－２，３－ジヒドロ－１ｈ－ベンゾ［ｅ］インドール二量体抗体 － 薬物コンジュゲート化合物、並びに使用及び処置の方法 |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| CA2928952A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| EP3082876B1 (en) | 2013-12-16 | 2018-01-17 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| UA118113C2 (uk) | 2013-12-16 | 2018-11-26 | Дженентек, Інк. | Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| TW201625688A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 經半胱胺酸改造之抗體及接合物 |
| JP2017533887A (ja) | 2014-09-17 | 2017-11-16 | ジェネンテック， インコーポレイテッド | ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート |
| EP3223854A1 (en) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| KR102111338B1 (ko) | 2015-10-02 | 2020-05-15 | 제넨테크, 인크. | 피롤로벤조디아제핀 항체 약물 콘쥬게이트 및 이의 사용 방법 |
| WO2017064675A1 (en) | 2015-10-16 | 2017-04-20 | Genentech, Inc. | Hindered disulfide drug conjugates |
| EP3365025B1 (en) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック， インコーポレイテッド | 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法 |
| US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| EP3496763B1 (en) | 2016-08-11 | 2026-04-01 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3612537B1 (en) | 2017-04-18 | 2022-07-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| CN110536703B (zh) | 2017-04-20 | 2024-07-12 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
| UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
| RS62928B1 (sr) | 2017-08-18 | 2022-03-31 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
| US10301319B2 (en) | 2017-09-20 | 2019-05-28 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| CN113272435B (zh) * | 2018-09-05 | 2025-11-14 | 加利福尼亚大学董事会 | 在多个主要组织相容性复合体分子上受限的ny-eso-1特异性t细胞受体的组合物 |
| TW202037381A (zh) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | 綴合化學降解誘導劑及使用方法 |
| EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| ES2967878T3 (es) | 2019-03-15 | 2024-05-06 | Medimmune Ltd | Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| CN117280219A (zh) | 2021-05-04 | 2023-12-22 | 阿斯顿科学公司 | Her2疫苗组合物 |
| KR20230017640A (ko) * | 2021-07-28 | 2023-02-06 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| EP4637833A2 (en) | 2022-12-23 | 2025-10-29 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| AU2024257248A1 (en) | 2023-04-17 | 2025-11-06 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014781A1 (en) * | 1992-01-24 | 1993-08-05 | The Regents Of The University Of California | Novel peptides and method for altering the activity of allosteric proteins |
| US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| EP1064022A4 (en) * | 1998-03-13 | 2004-09-29 | Epimmune Inc | HLA BINDING PROTEINS AND THEIR USE |
| WO1999057981A1 (en) * | 1998-05-08 | 1999-11-18 | Sloan-Kettering Institute For Cancer Research | Compositions and methods for active vaccination |
| AU780109B2 (en) * | 1999-01-29 | 2005-03-03 | Corixa Corporation | HER-2/neu fusion proteins |
-
2001
- 2001-08-14 PL PL01365789A patent/PL365789A1/pl not_active Application Discontinuation
- 2001-08-14 EP EP01975714A patent/EP1366153A2/en not_active Withdrawn
- 2001-08-14 CA CA002419533A patent/CA2419533A1/en not_active Abandoned
- 2001-08-14 AU AU2001295008A patent/AU2001295008A1/en not_active Abandoned
- 2001-08-14 MX MXPA03001389A patent/MXPA03001389A/es unknown
- 2001-08-14 CN CNA018164471A patent/CN1537164A/zh active Pending
- 2001-08-14 BR BR0113235-0A patent/BR0113235A/pt not_active Application Discontinuation
- 2001-08-14 US US09/930,125 patent/US20020193329A1/en not_active Abandoned
- 2001-08-14 IL IL15441501A patent/IL154415A0/xx unknown
- 2001-08-14 WO PCT/US2001/041733 patent/WO2002014503A2/en not_active Ceased
- 2001-08-14 KR KR10-2003-7002207A patent/KR20030048009A/ko not_active Withdrawn
- 2001-08-14 JP JP2002519631A patent/JP2004522412A/ja active Pending
- 2001-08-14 HU HU0600780A patent/HUP0600780A2/hu unknown
-
2003
- 2003-02-14 NO NO20030714A patent/NO20030714L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002014503A2 (en) | 2002-02-21 |
| KR20030048009A (ko) | 2003-06-18 |
| IL154415A0 (en) | 2003-09-17 |
| NO20030714D0 (no) | 2003-02-14 |
| NO20030714L (no) | 2003-04-11 |
| AU2001295008A1 (en) | 2002-02-25 |
| CA2419533A1 (en) | 2002-02-21 |
| US20020193329A1 (en) | 2002-12-19 |
| CN1537164A (zh) | 2004-10-13 |
| JP2004522412A (ja) | 2004-07-29 |
| MXPA03001389A (es) | 2004-05-04 |
| BR0113235A (pt) | 2004-06-08 |
| EP1366153A2 (en) | 2003-12-03 |
| WO2002014503A3 (en) | 2003-09-18 |
| HUP0600780A2 (en) | 2007-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0600780A2 (en) | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies | |
| HUP0200763A2 (en) | Compositions for the treatment and diagnosis of breast cancer and methods for their use | |
| AU2002339865A8 (en) | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors | |
| ATE307601T1 (de) | Brustkrebsbehandlung mittels natürlicher ätherischer öle | |
| NO20016427D0 (no) | Blandinger og fremgangsmåter for behandling av diagnose av lungekreft | |
| NO20010196D0 (no) | Sammensetninger og fremgangsmåter for terapi og diagnose av prostatakreft | |
| PL365244A1 (pl) | Kompozycje oraz sposoby leczenia i diagnozowania raka sutka | |
| DE10085007T1 (de) | Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes | |
| ATE300597T1 (de) | Behandlung von geweben | |
| HUP0203968A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| NO20024610D0 (no) | Synergistiske metoder og blandinger for behandling av kreft | |
| FIU20060389U0 (fi) | Luusairauksien hoito | |
| ZA200301204B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| AU5160201A (en) | Compositions comprising natural agents for treatment of cancer | |
| AU2002246519A8 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| DE60223576D1 (de) | Hautbehandlungszusammensetzung | |
| AU8678501A (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| PL366066A1 (pl) | Kompozycje oraz sposoby leczenia i diagnozowania raka sutka | |
| IL145397A0 (en) | Compositions and methods for treatment of cancer | |
| EP1349485A4 (en) | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA | |
| PL368035A1 (pl) | Kompozycje i sposoby leczenia raka | |
| NO994631D0 (no) | Fremgangsmaater og sammensetninger for behandling av eggstokkreft | |
| AU3483001A (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| ZA200108256B (en) | Compositions and methods for the treatment and diagnosis of breast cancer. | |
| PL350863A1 (en) | Compositions and methods for the treatment and diagnosis of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |